Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000482700300035&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.21873/anticanres.13505
eISSN
1791-7530
Externe Identifier
  • Clarivate Analytics Document Solution ID: IT2RU
  • PubMed Identifier: 31262883
ISSN
0250-7005
Ausgabe der Veröffentlichung
7
Zeitschrift
ANTICANCER RESEARCH
Schlüsselwörter
  • Chemotherapy
  • oncogene
  • pharmacogenomics
Paginierung
3585 - 3593
Datum der Veröffentlichung
2019
Status
Published
Titel
Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor
Sub types
  • Article
Ausgabe der Zeitschrift
39

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
DOI
10.21873/anticanres.13505
eISSN
1791-7530
ISSN
0250-7005
Ausgabe der Veröffentlichung
7
Zeitschrift
Anticancer Research
Sprache
en
Online publication date
2019
Paginierung
3585 - 3593
Datum der Veröffentlichung
2019
Status
Published
Herausgeber
Anticancer Research USA Inc.
Herausgeber URL
http://dx.doi.org/10.21873/anticanres.13505
Datum der Datenerfassung
2022
Titel
Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor
Ausgabe der Zeitschrift
39

Data source: Crossref

Abstract
<h4>Background</h4>The oncogenic role of epidermal growth factor receptor (EGFR) has been intensively studied. However, its emerging role in drug resistance has not been fully addressed.<h4>Materials and methods</h4>This study systematically investigated the correlation of mRNA and protein expression of EGFR, as well as gene amplification and mutations with the log-transformed half-maximal inhibitory concentration (log<sub>10</sub>IC<sub>50</sub>) values obtained from the NCI panel of 60 human tumor cell lines against 83 standard anticancer agents and the top 10 natural cytotoxic products previously screened by us.<h4>Results</h4>EGFR protein expression, rather than other measurements, was most frequently associated with drug response. Log<sub>10</sub>IC<sub>50</sub> and EGFR protein level were significantly positively correlated under all investigated DNA topoisomerase (TOPO) II inhibitors, followed by 81% of alkylating agents and platinum-based compounds, 71% of anti-hormones, 66% of TOPO I inhibitors and 50% of antibiotics. Furthermore, 60% of cytotoxic natural products did not reveal significant correlations.<h4>Conclusion</h4>Collectively, we showed a broad-spectrum of cross-resistance towards clinical drugs mediated by EGFR. Natural cytotoxic products may be further developed as novel drugs to overcome EGFR-associated resistance to clinically established anticancer drugs.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany.
Autoren
DOI
10.21873/anticanres.13505
eISSN
1791-7530
Externe Identifier
  • PubMed Identifier: 31262883
Open access
false
ISSN
0250-7005
Ausgabe der Veröffentlichung
7
Zeitschrift
Anticancer research
Schlüsselwörter
  • Cell Line, Tumor
  • Humans
  • Neoplasms
  • RNA, Messenger
  • Antineoplastic Agents
  • Drug Resistance, Neoplasm
  • ErbB Receptors
Sprache
eng
Medium
Print
Paginierung
3585 - 3593
Datum der Veröffentlichung
2019
Status
Published
Datum der Datenerfassung
2019
Titel
Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
39

Data source: Europe PubMed Central

Abstract
BACKGROUND: The oncogenic role of epidermal growth factor receptor (EGFR) has been intensively studied. However, its emerging role in drug resistance has not been fully addressed. MATERIALS AND METHODS: This study systematically investigated the correlation of mRNA and protein expression of EGFR, as well as gene amplification and mutations with the log-transformed half-maximal inhibitory concentration (log10IC50) values obtained from the NCI panel of 60 human tumor cell lines against 83 standard anticancer agents and the top 10 natural cytotoxic products previously screened by us. RESULTS: EGFR protein expression, rather than other measurements, was most frequently associated with drug response. Log10IC50 and EGFR protein level were significantly positively correlated under all investigated DNA topoisomerase (TOPO) II inhibitors, followed by 81% of alkylating agents and platinum-based compounds, 71% of anti-hormones, 66% of TOPO I inhibitors and 50% of antibiotics. Furthermore, 60% of cytotoxic natural products did not reveal significant correlations. CONCLUSION: Collectively, we showed a broad-spectrum of cross-resistance towards clinical drugs mediated by EGFR. Natural cytotoxic products may be further developed as novel drugs to overcome EGFR-associated resistance to clinically established anticancer drugs.
Date of acceptance
2019
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/31262883
DOI
10.21873/anticanres.13505
eISSN
1791-7530
Ausgabe der Veröffentlichung
7
Zeitschrift
Anticancer Res
Schlüsselwörter
  • Chemotherapy
  • oncogene
  • pharmacogenomics
  • Antineoplastic Agents
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm
  • ErbB Receptors
  • Humans
  • Neoplasms
  • RNA, Messenger
Sprache
eng
Country
Greece
Paginierung
3585 - 3593
PII
39/7/3585
Datum der Veröffentlichung
2019
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2019
Titel
Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
39

Data source: PubMed

Beziehungen:
Property of

Tools